Amneal Pharmaceuticals launches mesalamine 800 mg delayed-release tablets, an aminosalicylate indicated for the treatment of moderately active ulcerative colitis in adults. Additionally, it has received approval from the US FDA for its Abbreviated New Drug Application (ANDA) for lenalidomide capsules in 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg strengths. Lenalidomide, a thalidomide analog, is indicated for the treatment of several blood cancers.